AstraZeneca puts $37.5 million behind a deeper Immunai partnership

Immunai’s latest funding disclosure looks less like a traditional venture round and more like a vote from a strategic customer. The healthtech company said AstraZeneca is expanding its AI partnership in a deal worth $37.5 million. No round type was disclosed, and no lead investors were listed.

Immunai builds an immune-focused drug discovery and development platform that combines wet-lab work, multiomic data, single-cell analysis, machine learning and functional genomics to help pharma companies make decisions across target discovery, preclinical evaluation and clinical trial optimization.

The clearest indication of where the new money is aimed comes from Immunai’s own description of the AstraZeneca relationship: on its website, the company highlights the AstraZeneca-Immunai partnership as focused on IBD target discovery. More broadly, Immunai says its platform is designed to identify novel disease-linked targets, prioritize drug candidates for development, and improve clinical trial strategy by clarifying mechanism of action, patient selection and treatment approaches.

That positioning matters because Immunai is not presenting itself as a general AI software vendor. Its pitch is centered on decoding the immune system for biopharma. The company says it is “mapping the immune system at unprecedented scale & resolution” and points to AMICA, which it describes as the world’s largest immune-focused, harmonized single-cell database. Its workflow starts with generating high-quality multiomic data from clinical and preclinical samples, then augmenting that data with immune knowledge, computing new immune features with machine learning, validating hypotheses in the lab, and producing recommendations for drug development teams.

The AstraZeneca expansion also sits within a broader collaboration model. Immunai says it partners with top biopharmaceutical companies and research institutions, and it spotlights another pharma collaboration with Teva around vitiligo disease mechanism and biomarker discovery for Teva’s IL15 targeted antibody.

For Immunai, the message in this announcement is straightforward: the company is monetizing its platform through deep pharma partnerships tied to specific therapeutic questions. In this case, AstraZeneca is putting $37.5 million into expanding that relationship, with Immunai’s immune-system mapping and target discovery work at the center of the arrangement.